Business Context and Reporting Period
Company: Humacyte, Inc. (HUMA)
Filing Type: Form 8-K (Current Report)
Report Date: November 21, 2025
Event Date: November 21, 2025 (Notice of termination delivered)
Effective Date: December 1, 2025 (10 days after notice)
The Company is an emerging growth company incorporated in Delaware. This filing reports the termination of a material definitive agreement regarding an equity distribution program.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The document is a current report focused solely on the termination of a specific contractual agreement.
Material Changes
- Termination of ATM Agreement: The Company terminated its Open Market Sale Agreement (ATM) with Jefferies LLC, originally entered into on September 1, 2022.
- Agreement Capacity: The terminated agreement allowed for the sale of common stock with an aggregate offering price of up to $80,000,000.
- Penalties: The Company is not subject to any termination penalties related to this action.
Guidance, Outlook, and Risks
Management Commentary: The filing states the termination was executed via notice delivered on November 21, 2025, with no further commentary on strategic rationale provided in this specific document.
Risks and Contingencies: No new risks or contingencies are disclosed in this filing. The termination is effective 10 days post-notice without financial penalty.
Investor Verification Checklist
- Verify the remaining balance of shares authorized under the terminated ATM agreement prior to termination.
- Confirm the effective date of termination (December 1, 2025) to ensure no sales occurred after the notice period.
- Review subsequent filings to determine if the Company intends to enter into a new equity distribution agreement.
- Check the Company's most recent 10-Q or 10-K for the latest liquidity position, as this 8-K does not provide updated cash balances.